Lipid-based Therapeutics Addressing Cancer and Complex Diseases

Our unique lipid structures can navigate complex biological systems such as the tumor microenvironment and the immune system for novel treatments of cancer, autoimmune, metabolic and other diseases

The Highfield Advantage

Our products are high-quality lipid nanoparticles designed with a unique modular system to be biocompatible as they travel in circulation and highly efficient in finding diseased tissues. These nanoparticles, optimized for targeting multiple disease mechanisms and cells, can safely carry various payloads in specific quantities for maximum efficacy.

HighField CEO Talks

Hear Dr. Yuhong Xu, Scientific Founder & CEO of HighField Bio talk, in her own words,
about the science behind HighField’s lipid nanostructures.

No. 1: Initial clinical data analysis of HighField ADCplex – presented at ASCO 2025 Meeting.

No. 2: Report on first patient dosing of HF50, Liposomal T cell engager.

No. 3: Report on first patient dosing of HF50, Liposomal T cell engager.

No. 4: Learn about T cell engaging complexes and Highfield’s new T cell transducing complexes

HighField News

Press Releases

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

•

April 21, 2025

HighField in the News

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Our unique lipid structures can navigate complex biological systems such as the tumor microenvironment and the immune system for novel treatments of cancer, autoimmune, metabolic and other diseases.